Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Aaron T. Gerds, MD MS, Michael R. Savona, MD, Bart L. Scott, MD, Moshe Talpaz, MD, Miklos Egyed, Claire N Harrison, Professor, Abdulraheem Yacoub, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Jennifer O'Sullivan, Sarah A Buckley, MD, Diane R. Mould, PhD, Shanthakumar Tyavanagimatt, PhD, Jennifer A. Smith, PhD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 667.

https://doi.org/10.1182/blood-2019-129293

Published: 2019

Journal Articles

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Claire N Harrison, Professor, Aaron T. Gerds, MD MS, Jean-Jacques Kiladjian, MD PhD, Konstanze Döhner, Sarah A Buckley, MD, Jennifer A. Smith, PhD, Adam R Craig, MD PhD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4175.

https://doi.org/10.1182/blood-2019-129245

Published: 2019

Journal Articles

Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

Ruben A. Mesa, MD, Moshe Talpaz, MD, Jean-Jacques Kiladjian, MD PhD, Claire N Harrison, Professor, Srdan Verstovsek, MD PhD, Sarah A Buckley, MD, Karisse Roman-Torres, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 4195.

https://doi.org/10.1182/blood-2019-124129

Published: 2019

Journal Articles

Targeting Activated Signaling Pathways for the Treatment of IKZF1 -Deleted B Lymphoblastic Leukemia

Rohit Gupta, BA, Jason H. Rogers, MS, Xin Long, PhD, Geraldo Medrano, BS, Jaime M. Reyes, BS, Michele Redell, MD PhD, Zachary T Ball, PhD, Margaret Goodell, PhD, Rachel E. Rau, MD

Blood (2019) 134 (Supplement_1): 3789.

https://doi.org/10.1182/blood-2019-127209

Published: 2019

Journal Articles

The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden

Srdan Verstovsek, MD PhD, Bart L. Scott, MD, Jason A Taylor, MD PhD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 1674.

https://doi.org/10.1182/blood-2019-127609

Published: 2019

Journal Articles

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Jennifer O'Sullivan, MD, Jason A Taylor, MD PhD, Aaron T. Gerds, MD MS, Sarah A Buckley, MD, Claire N Harrison, Professor, Stephen T. Oh, MD, Kieran Howard, Helene Marie-Pierre Dreau, PhD, Angela Hamblin, MD PhD, Adam J. Mead, MD PhD

Blood (2019) 134 (Supplement_1): 4214.

https://doi.org/10.1182/blood-2019-129254

Published: 2019

Journal Articles

Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients

Blood (2018) 132 (Supplement 1): 4277.

https://doi.org/10.1182/blood-2018-99-116289

Published: 2018

Journal Articles

Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)

Ruben A. Mesa, MD FACP, Francisco Cervantes, MD PhD, Claire N. Harrison, MD DM, FRCP, PRCPath, Adam J. Mead, MD PhD, Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD, Lixia Wang, PhD, Tanya Granston, PhD, John Mascarenhas, MD

Blood (2018) 132 (Supplement 1): 4281.

https://doi.org/10.1182/blood-2018-99-114779

Published: 2018

Journal Articles

Myelofibrosis Drug Development through the Decade: Novel JAK Inhibitors

Ali Younas Khan, MD, Muhammad Junaid Tariq, MD, Muhammad Usman, MD, Awais Ijaz, MD, Abdul Rafae, MD, Mustafa Nadeem Malik, MD, Hafiz Muhammad Fazeel, MD, Nadia Carenina Nunes Cavalcante Parr, MD, Muhammad Asad Fraz, MD, Muhammad Jahanzeb Khalil, MD, Jemin Aby Jose, MD, Seren Durer, MD, Ceren Durer, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5477.

https://doi.org/10.1182/blood-2018-99-115408

Published: 2018

Journal Articles

Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations

Markus Vaha-Koskela, PhD, Muhammad Ammad-ud-din, PhD, Kirsi Siivola, MSc, Tanja Ruokoranta, MSc, Laura Turunen, PhD, Kimmo Porkka, MD PhD, Pedro Marques Ramos, PhD, Celine Pallaud, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD

Blood (2018) 132 (Supplement 1): 2743.

https://doi.org/10.1182/blood-2018-99-116391

Published: 2018

Journal Articles

The role of JAK2 inhibitors in MPNs 7 years after approval

Francesco Passamonti, Margherita Maffioli

Blood (2018) 131 (22): 2426–2435.

https://doi.org/10.1182/blood-2018-01-791491

Published: 2018

Journal Articles

Between a Rux and a Hard Place: Investigating Causes of Ruxolitinib Discontinuation, Salvage Treatment and Outcome in Myelofibrosis

Savan Shah, MD, Chetasi Talati, MD, Najla Al Ali, M.Sc, Eric Padron, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Alan F. List, MD, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD, Andrew Kuykendall, MD

Blood (2017) 130 (Supplement 1): 4186.

https://doi.org/10.1182/blood.V130.Suppl_1.4186.4186

Published: 2017

Journal Articles

Targeted Inhibition of STAT/TET1 Axis As a Potent Therapeutic Strategy for Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 857.

https://doi.org/10.1182/blood.V130.Suppl_1.857.857

Published: 2017

Journal Articles

Targeting JAK2 Kinase Promotes Foxp3 Stability and Function of CD8iTregs in Prevention of Graft-Versus-Host Disease

Supinya Iamsawat, Anusara Daenthanasanmak, Jessica H. Voss, PhD, Hung D Nguyen, PhD, Xue-Zhong Yu, MD MS

Blood (2017) 130 (Supplement 1): 165.

https://doi.org/10.1182/blood.V130.Suppl_1.165.165

Published: 2017

Journal Articles

JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Prithviraj Bose, Srdan Verstovsek

Blood (2017) 130 (2): 115–125.

https://doi.org/10.1182/blood-2017-04-742288

Published: 2017

Journal Articles

Relationship of JAK2 V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)

Alessandro M. Vannucchi, Adam Mead, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, Andrew Perkins, Jiri Mayer, Peter Ganly, Harry C. Schouten, Patrizia Tosi, Charles Michael Farber, Pierre Zachee, Jean-Jacques Kiladjian, Jyoti Nangalia, James P. Dean, Huafeng Zhou, Jack W. Singer, Ruben A. Mesa, Claire N. Harrison

Blood (2016) 128 (22): 3131.

https://doi.org/10.1182/blood.V128.22.3131.3131

Published: 2016

Journal Articles

Pacritinib Targets IRAK1 and Shows Synergy with HDAC and BET Inhibitors in Acute Myeloid Leukemia

Alka Puri, PhD, Shawn Mahmood, B.S., B.A., Bernadette Maertens, Monika Davare, PhD, Stephen E Kurtz, PhD, Cristina E. Tognon, Christopher O. Eden, BA, Johannes Elferich, PhD, Ujwal Shinde, PhD, Brian J. Druker, MD, Jack W. Singer, Anupriya Agarwal

Blood (2016) 128 (22): 3514.

https://doi.org/10.1182/blood.V128.22.3514.3514

Published: 2016

Journal Articles

Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl

Blood (2016) 128 (22): LBA-5.

https://doi.org/10.1182/blood.V128.22.LBA-5.LBA-5

Published: 2016

Journal Articles

Superior Activity of BET Protein Bromodomain Antagonist-Based Combination with JAK Kinase, PIM Kinase or Heat Shock Protein 90 Inhibitor Against Post-MPN-MF sAML Cells

Dyana T Saenz, Warren Fiskus, PhD, Taghi Manshouri, PhD, Baohua Sun, MD PhD, Stephanie Krieger, Simrit Parmar, MD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2015) 126 (23): 1269.

https://doi.org/10.1182/blood.V126.23.1269.1269

Published: 2015

Journal Articles

Comparison of Ruxolitinib , Momelotinib, and Pacritinib in the Inhibition of Immune Differentiation and Proliferation of T Cells in Myeloproliferative Neoplasm

Chi Chen, MD PhD, Hemant Sindhu, MD, Ajay Kundra, MD, Maryna Yarotska, MD, Tony W. Cheung, MD, Jen-Chin Wang, MD

Blood (2015) 126 (23): 5203.

https://doi.org/10.1182/blood.V126.23.5203.5203

Published: 2015

NARROW

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

Targeting Activated Signaling Pathways for the Treatment of IKZF1 -Deleted B Lymphoblastic Leukemia

The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients

Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)

Myelofibrosis Drug Development through the Decade: Novel JAK Inhibitors

Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations

The role of JAK2 inhibitors in MPNs 7 years after approval

Between a Rux and a Hard Place: Investigating Causes of Ruxolitinib Discontinuation, Salvage Treatment and Outcome in Myelofibrosis

Targeted Inhibition of STAT/TET1 Axis As a Potent Therapeutic Strategy for Acute Myeloid Leukemia

Targeting JAK2 Kinase Promotes Foxp3 Stability and Function of CD8iTregs in Prevention of Graft-Versus-Host Disease

JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Relationship of JAK2 V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)

Pacritinib Targets IRAK1 and Shows Synergy with HDAC and BET Inhibitors in Acute Myeloid Leukemia

Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl

Superior Activity of BET Protein Bromodomain Antagonist-Based Combination with JAK Kinase, PIM Kinase or Heat Shock Protein 90 Inhibitor Against Post-MPN-MF sAML Cells

Comparison of Ruxolitinib , Momelotinib, and Pacritinib in the Inhibition of Immune Differentiation and Proliferation of T Cells in Myeloproliferative Neoplasm

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only